Luminera Derm News
2 articles
growth-positive
Looking $100 million
American pharmaceutical giant AbbVie has announced the acquisition of Israeli aesthetic medicine company Luminera Derm. The acquisition price is estimated at $100 million. Luminera Derm, which develops and markets subcutaneous injection products, has annual revenue in the tens of millions of dollars. The acquisition will be made through Allergan, one of the worlds leading aesthetic medicine companies. Luminera Derms leading innovation, HArmonyCa, is one of the main reasons for the acquisition. The acquisition will provide Luminera Derm with the capital needed to conduct clinical trials and expand its product portfolio. The company had faced challenges due to the COVID-19 pandemic, but has seen a rebound in revenue as markets reopened. The acquisition is expected to have a positive impact on AbbVies growth.
AcquisitionExpand
growth-positive
AbbVie buys Israeli aesthetic medicine co Luminera
AbbVies unit Allergan Aesthetics has entered into an agreement to acquire Israeli company Luminera Derm, which has a portfolio and pipeline of dermal filler products. The financial details of the acquisition were not disclosed, but it is believed to be several hundred million dollars. The acquisition is expected to contribute to AbbVies growth in the aesthetics market and enhance its product offering for healthcare professionals and patients globally. Lumineras lead product, HArmonyCa, is a differentiated dermal filler that combines hyaluronic acid with calcium hydroxyapatite. The acquisition is a strategic move for AbbVie to strengthen its position in the dermal filler category.
Acquisition
